Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15708MR)

This product GTTS-WQ15708MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15708MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3085MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ5317MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ10297MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ2672MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ15314MR IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA TNFR55-Ig1
GTTS-WQ12029MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ12496MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NOE-102
GTTS-WQ279MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW